Bionsight @ Merck Research Grants

Bionsight selected as the finalist team in 2022 Merck Research Grants.

Bionsight was selected as the finalist 8 teams out of a total of 1147 applications with the category, AI for Predictive Diagnostics & Therapeutic Target Discovery. Bionsight researches the chemoproteomics platform which is based on high-resolution mass spec. Our chemoproteomics platform, Javelin detects protein-ligand interactions at a proteome-wide scale. It has a wide range of applications from target identification, validation, high throughput screening, and novel target discovery. We believe chemoproteomics is an emerging technology and has a lot of potential for drug-discovery.